For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: September 21–25, 2026
Innovation watch FDA approves the first treatment for Sanfilippo syndrome. On September 17, the FDA approved Ultragenyx’s Fayuvi, a one-time…
Blog
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
Search Posts
Op-Eds
Vaccine Disease Protections Outweigh Side Effects
It’s quite unusual for me to write follow-up columns, but I had such an overwhelming response to my recent column…
Op-Eds
Give Nestlé a Break
Generally, the European left has no love for big American financial firms. But some Swiss shareholder activists have embraced the U.S.’s largest proxy-advisory service in…
Washington Post
Painkiller Decision suggest shift in FDA’s risk-benefit equation
Op-Eds
Nation Descends into Mercury Madness
Mercury is all over the news these days, which is appropriate for an element named after the messenger of the gods. At some Maryland high…
Citation
Americans told fish tales about mercury hazards in fish consumption
Products
The Drug Reimportation Controversy
As policy battles go, the drug reimportation debate is an unusual one. On its face, the federal ban on reimporting pharmaceuticals appears to violate the…